David Ranson will be presenting the Deflexifol opportunity to potential investors in Singapore, Hong Kong and Shanghai as part of AusBiotech’s Asian Investment Series, March 21 – 28, 2017. See http://ausbiotechinvestment.com.au/ for more details.
Deflexifol (formerly Fluorodex) maintains in-vitro potency, overcomes incompatibility of 5-fluorouracil and folinic acid and may reduce phlebitis, catheter blockages and thromboembolic events. Development and assessment of novel all-in-one parenteral formulations with integrated anticoagulant properties for the concomitant delivery of 5-fluorouracil and calcium folinate. Read our article signalling improved patient outcomes from Deflexifol.